Patent for Klaria’s Sumatriptan Alginate Film Granted in Russia
Klaria’s patent for Sumatriptan Alginate Film has been granted in Russia. This grant extends the global patent protection for Klaria’s most advanced development program. The period of patent protected exclusivity in the Russian Federation will last until 2037.
UPPSALA, 10 February, 2021. The granted Sumatriptan Alginate Film patent protects the combination of the active substance, Sumatriptan, with the Alginate Film. The period of patent protected exclusivity in Russian will last until 2037. This granting of the Sumatriptan Alginate Film patent is the third granting of this patent world-wide, with the patent having been granted in the United States in 2021 and in Mexico in January, 2022.
Jesper Wiklund, CEO of Klaria said “This approval marks the third time our Sumatriptan Alginate Film patent is granted. With this grant, we expand the global patent protection for our most advanced clinical development program, Sumatriptan Alginate Film. This strengthens the commercial potential of the project with market exclusivity until 2037 in Russia. We note that the patent continues to be granted on a world-wide basis and we look forward to extending this track record of success as the patent makes its way through the granting process in patent offices world-wide.”
About KL-00119: KL-00119 is an alginate-based oral trans-mucosal film. KL-00119 is the first oral trans-mucosal migraine product and is designed to be a significant improvement to all available acute migraine treatments available to patients today, particularly in patients suffering from migraine-induced nausea and vomiting. KL-00119 is also particularly suited for the treatment of migraine in pediatric populations. KL-00119 is a unique molecular dispersion of the active antimigraine drug sumatriptan. The KL-00119 film presents sumatriptan to the oral mucosal surface in a unique way to allow rapid, consistent absorption with the lowest possible burden on the patient. The base film-forming alginate and the sumatriptan-containing films have been the subject of comprehensive intellectual property protection, thus ensuring prolonged market exclusivity. The uniqueness and promise of the KL-00119 has been confirmed by the project being awarded the exclusive European Commission Horizon 2020 Innovation Grant in 2018 (Grant Number 8296159).
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.